Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Recurrence 1Neoplasm Metastasis 1Melanoma 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 11Radiotherapy 11Filgrastim 6Granulocyte Colony-Stimulating Factor 4Chemotherapy, Adjuvant 4etoposide phosphate 3Topotecan 3O(6)-benzylguanine 3Melphalan 3Etoposide 3Cyclophosphamide 3Carboplatin 3sodium thiosulfate 2sargramostim 2Thiotepa 2Radiotherapy, Intensity-Modulated 2Methylphenidate 2Mannitol 2Ifosfamide 2Carmustine 2Busulfan 2Bone Marrow Transplantation 2Bevacizumab 2transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38) 1temsirolimus 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1poly ICLC 1pentetreotide 1pemigatinib 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Central Nervous System Neoplasms × Maintenance × Clear all
NCT03690869 2025-04-08

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Regeneron Pharmaceuticals

Phase 1/2 Terminated
57 enrolled 31 charts
CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Recurrence, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡